Clinical Research Directory
Browse clinical research sites, groups, and studies.
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia
Sponsor: Tufts Medical Center
Summary
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug
Official title: Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-04-15
Completion Date
2028-05-01
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
veverimer daily
8 weeks of taking 9 grams of veverimer (a powder mixed into water) daily
veverimer every other day
8 weeks of taking 9 grams of veverimer (a powder mixed into water) every other day
Placebo
8 weeks taking 9 grams microcrystalline cellulose (powdered mixed into water) daily or every other day
Locations (1)
Tufts Medical Center
Boston, Massachusetts, United States